Cullinan Therapeutics, Inc. (CGEM) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on November 3, 2025, by Cullinan Therapeutics, Inc., a biopharmaceutical company based in Cambridge, Massachusetts. The filing discloses the presentation of new clinical data from the Phase 1 study of its investigational therapy, CLN-049, at the 67th American Society of Hematology (ASH) Annual Meeting in December 2025.
Key Clinical Metrics and Results
The filing details efficacy and safety data as of a June 2025 cutoff for 40 enrolled patients (34 with relapsed/refractory acute myeloid leukemia [AML] and 6 with myelodysplastic syndrome [MDS]).
- Efficacy in AML: Among 29 efficacy-evaluable AML patients, anti-leukemic activity was observed at target doses ≥6 μg/kg (n=23).
- Response Rates: The composite complete response (CRc) rate was 30% and the overall response rate (ORR) was 57% at doses ≥6 μg/kg. At the highest dose of 12 μg/kg (n=13), CRc was 31% and ORR was 69%.
- Minimal Residual Disease (MRD): Of 23 patients with bone marrow blasts <5%, 33% (n=3) were MRD negative. No relapse was observed in MRD-negative patients.
- TP53 Mutations: Among five patients with TP53-mutated AML treated at 12 μg/kg, four responses were observed (2 CRh, 2 MLFS).
- Safety Profile: The most common treatment-emergent adverse events (TEAEs) were cytokine release syndrome (CRS) at 40% and infusion-related reactions at 35%. All CRS events were Grade 1 or 2. Grade ≥3 TEAEs occurring in >10% of patients included febrile neutropenia, white blood cell count decrease (17.5% each), and pneumonia (12.5%).
Material Changes and Outlook
This filing represents a significant update on the clinical development of CLN-049, demonstrating promising activity in a heavily pretreated population. The study is ongoing with dose escalation continuing. Management highlights the manageable safety profile and the potential of the therapy in patients with high-risk genetic features, such as TP53 mutations.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed patient demographics and specific response durations.
- Confirm the timeline for the presentation of these data at the ASH Annual Meeting in December 2025.
- Monitor future filings for updates on the dose escalation phase and any new safety signals as the patient cohort expands.
- Note that this 8-K does not contain financial statements, revenue, or cash flow data; refer to the most recent 10-Q or 10-K for financial metrics.